YourWay Cannabis

XPHYTO THERAPEUTICS (OTCMKTS: XPHYF) STOCK QUOTE

Last Trade: US$0.32 -0.03 -9.33
Volume: 2,110
5-Day Change: -1.00%
YTD Change: -1.00%
Market Cap: US$20.410M

LATEST NEWS FROM XPHYTO THERAPEUTICS

July 18, 2022
XPhyto Therapeutics Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease
XPhyto Therapeutics Corp. (CSE:XPHY),(OTCQB:XPHYF), (FSE:4XT) ("XPhyto" or the "Company") is pleased to report a significant potential market opportunity for its oral dissolvable ("ODF") biosensor screening tests for oral inflammation. Certain buprenorphine medicines prescribed to treat opioid use disorder ("OUD") and pain have been recently associated with numerous serious oral health problems requiring medical... Read More
July 15, 2022
XPhyto Therapeutics Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease
XPhyto Therapeutics Corp. (CSE:XPHY),(OTCQB:XPHYF), (FSE:4XT) ("XPhyto" or the "Company") is pleased to report a significant potential market opportunity for its oral dissolvable ("ODF") biosensor screening tests for oral inflammation. Certain buprenorphine medicines prescribed to treat opioid use disorder ("OUD") and pain have been recently associated with numerous serious oral health problems requiring medical... Read More
June 8, 2022
XPhyto Therapeutics Adds Pharmaceutical Manufacturing Expert Dr. Florian A. Sahr to Its European Team
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to report that Dr. Florian A. Sahr has joined its European operations as Head of Project Management. Dr. Sahr is a German-born and internationally trained leader in drug formulation, technology transfer and new-product manufacturing. Dr. Sahr has a strong track record of drug development, including transdermal ("TDS") and oral... Read More
May 9, 2022
XPhyto Therapeutics Reports Product Developments on Platform-Based Rotigotine Transdermal Patch for Parkinson’s Disease
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a product development report on its Rotigotine transdermal ("TDS") patch, including results of its recent human cadaver skin permeation study, first announced April 4, 2022. The Company's Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH... Read More
April 11, 2022
XPhyto Therapeutics, Biosensors Market and Product Developments on Platform-Based Oral Dissolvable Biosensors for Oral Health and Infectious Disease
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a market and product development report on its Sublingual oral dissolvable film ("ODF") biosensor development pipeline. The Company's oral dissolvable products are based on the ODF platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), which incorporates proprietary... Read More
April 4, 2022
XPhyto Therapeutics Reports Market and Product Developments on Platform-based Rotigotine Transdermal Patch for Parkinson's Disease
XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a market and product development report on its Rotigotine transdermal ("TDS") patch. The Company's Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"). Rotigotine is a non-ergoline dopamine agonist approved for the treatment of... Read More
March 31, 2022
XPhyto Therapeutics Closes First Tranche of Financing
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that further to its news release of March 25, 2022, it has closed the first tranche of its private placement. The Company issued 1,250,000 common shares at $1.00 per share for total gross proceeds of $1,250,000. The Company paid $100,000 and issued 100,000 share purchase warrants in finder's fees with respect to the... Read More
February 22, 2022
XPhyto Provides Progress Update on Psychedelic Medicine Programs and Novel Compounds Milestone
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on its wholly owned subsidiary XPhyto Laboratories Inc. ("XPhyto Labs"). XPhyto Labs' psychedelic medicine programs based in Edmonton, Canada, are focused on a multi-pronged approach to psychedelic medicine including GMP drug synthesis, proprietary drug delivery systems, novel psychedelic analogue... Read More
February 8, 2022
XPhyto Reports on its Three Primary Business Divisions
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to report on its three business divisions as part of its product development, commercialization, and revenue growth strategy: I) Vektor Pharma, II) 3a-diagnostics, and III) XPhyto Laboratories. Vektor Pharma Vektor Pharma TF GmbH ("Vektor Pharma"), based in Uttenweiler, Baden-Württemberg, Germany, is a 100% wholly owned... Read More
January 24, 2022
XPhyto Provides Update on Integration of 3a-diagnostics GmbH
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the integration of 3a-diagnostics GmbH ("3a") into XPhyto's German operations. The acquisition of 3a, announced December 6, 2021, is a primary driver of XPhyto's recent management activities in Germany. The Company has been working diligently to expedite the launch of its COVID-ID lab test system into... Read More
January 17, 2022
XPhyto Announces Head of Sales, Europe
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Mr. Drahoslav Zdarek as the Company's Head of Sales, Europe. Mr. Zdarek will focus on building out distribution, sales and marketing of the Company's products, with high priority on the commercialization of Covid-ID Lab, the Company's German CE Mark approved rapid RT-PCR test registered within... Read More
January 10, 2022
XPhyto Announces New Director of Business Development and Head of Diagnostic Research
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce two key appointments to continue its focus on research, development and commercialization of its biosensor and diagnostic products including for the detection of COVID-19. Director of Business Development Mr. Roland Spleiss has joined as the Director of Business Development. Mr. Spleiss is a seasoned commercial... Read More
December 15, 2021
XPhyto Epilepsy Clinical Trial Planned in 2022 with Its Proprietary Fast-Dissolving CBD Oral Strips
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the development of its fast-dissolving CBD oral strips. With significant complexities involved in the planning and preparation for the pending human pilot study, the Company is pleased to announce that its European human CBD bioavailability study will commence in January 2022. Prof. Dr. Beckert said,... Read More
December 6, 2021
XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH
The acquisition positions XPhyto to be a leading Biosensor producer integrating thin film technology with 3a-diagnostics biosensor technology The acquisition of 3a, a German-based rapid point-of-care diagnostics firm adds IP and a deeply experienced scientific expertise to XPhyto Gains technical and business synergies Secures XPhyto a near-term infectious disease biosensor portfolio and related Intellectual Property XPhyto... Read More
December 3, 2021
XPhyto Therapeutics Announces Stock Option Grants
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) (the " Company " or " XPhyto ") announces that it has issued an aggregate of 1,850,000 stock options (the " Options ") in accordance with the Company's stock option plan (the " Option Plan ") at an exercise price of $1.25 per share. 1,750,000 Options will expire on November 29, 2026 and 100,000 Options will expire on November 29, 2023. The Options were granted to... Read More
November 26, 2021
XPhyto Therapeutics Closes Private Placements for Gross Proceeds of $7,000,0000
XPhyto Therapeutics Corp. (" XPhyto " or the " Company ") (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) is pleased to announce that further to its news release dated November 3, 2021, it has now closed its $1.00 common share non-brokered private placement (the " Equity Offering "), as well as its previously announced non-brokered convertible debenture unit offering (the " Debenture Offering "). The Equity Offering resulted in the... Read More
November 19, 2021
XPhyto Announces CFO Appointment
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Mr. Joseph Meagher as Chief Financial Officer of the Company. Mr. Meagher is a Chartered Professional Accountant (CPA, CA) and a Chartered Director (C.Dir.). He is currently the CFO of Defence Therapeutics Corp (CSE:DTC), a publicly-traded biotechnology company engineering next generation... Read More
November 3, 2021
XPhyto Announces Managing Director Appointment, Financing and 3a-diagnostics Development
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Prof. Dr. Thomas Beckert as the managing director of XP Diagnostics GmbH, a 100% owned subsidiary of XPhyto. With the next phase of growth and development, Prof. Dr. Thomas Beckert will be appointed to the position of managing director of XP Diagnostics GmbH to run XPhyto's operations in Germany... Read More
October 12, 2021
XPhyto Reports Development Update for its Drug Delivery Business
Rotigotine transdermal skin patch optimization and pivotal study planning underway Rotigotine patch manufacturing, sales and marketing in preparation Cannabinoid oral dissolvable film (ODF) programs advanced, CBD ODF ready for pilot study Prioritization of additional near-term drug formulation programs underway XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce... Read More
October 8, 2021
Xphyto Announces Engagement of Consultants for Marketing and Promotional Activities
XPhyto Therapeutics Corp. ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto" or the" Company ") announces it has entered into extensions to investor relations consulting agreements with each of Knox Communications Inc. (" KCI ") and M. Davis & Associates Capital Inc. (" Davis "), to carry out marketing and investor communications activities for the Company. KCI's engagement is extended for a 12 month period beginning on October... Read More
September 8, 2021
XPhyto Reports Successful Market Launch and Growing Demand for its 25-minute COVID-19 PCR Test COVID-ID Lab
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the successful market launch of its 25-minute COVID-19 PCR Test COVID-ID Lab. The pilot project at the test centers in Berlin has successfully optimized the operational procedures and protocols for the rapid, efficient and reliable use of COVID-ID Lab. This technical and operational knowledge is a critical... Read More
August 30, 2021
XPhyto Launches First Commercial Biosensor for Oral Disease
Biosensor test dissolves on the tongue and turns bitter indicating the presence of oral inflammation after five minutes Easy and simple at-home self-checks improve oral health and indicate inflammation early on Test successfully registered with the German authorities and is ready for partnering with wholesale distribution partners and market launch The global Biosensor market is expected to cross USD 38.7 billion by 2027 at... Read More
July 28, 2021
XPhyto’s Acquisition Target, 3a-Diagnostics, Reports Breakthrough Identification of COVID-19 Biosensor Candidates
First saliva activated biosensor molecules identified to diagnose COVID-19 infection using XPhyto's oral dissolvable delivery platform Biosensor candidates are ready for optimization and performance assessment Development of biosensor screening test would expand XPhyto's diagnostic product pipeline for COVID‑19 and additional infectious diseases Biosensor candidates present an innovative low-cost diagnostic alternative... Read More
July 20, 2021
XPhyto Signs Transformative Acquisition Agreement With 3a-Diagnostics, to Enter Hi-Tech Biosensor Market and Expand Its Diagnostic Product Portfolio
The acquisition creates significant commercial development and manufacturing opportunities for XPhyto as well as cost synergies and improved margins on its diagnostic products. The acquisition secures XPhyto an experienced research and development team with a pipeline of ready-to-launch biosensor products. The acquisition facilitates XPhyto's aggressive expansion into the point-of-care biosensor market which is growing at 8%... Read More
July 2, 2021
XPhyto Announces Advertising Agreement with Agora Internet Relations Corp.
VANCOUVER, BC / ACCESSWIRE / July 2, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") announces that pursuant to its advertising agreement with AGORA Internet Relations Corp. ("AGORA") dated December 1, 2020 (the "Advertising Agreement"), the Company issued 7.957 common shares on June 17, 2021 to AGORA in consideration for advertising services provided to the Company during the... Read More
June 30, 2021
XPhyto Supplies 10 Test Centers in Berlin with 25-minute COVID-19 PCR Test
XPhyto signs master supply agreement with operator of 10 COVID-19 test centers The test will be offered to customers as a rapid PCR test with sample processing on site Commercial operations expected to commence upon delivery of kits XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that it has signed a master supply agreement with Beovita GmbH & Co. KG and... Read More
June 15, 2021
XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands... Read More
June 8, 2021
XPhyto Provides Progress Report on Mescaline Program for Psychedelic Therapies
Research and development lab set up, preliminary mescaline synthesis complete Modified synthesis process developed, mescaline batches manufactured Development of analytical methods and validation, GMP standard operating procedures and manufacturing scale-up underway XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its GMP mescaline synthesis program is on... Read More
May 20, 2021
XPhyto Rapid Point-of-Care COVID-19 PCR Test Offered for Sale in Germany
Rapid 25-minute point-of-care COVID-19 PCR test available for purchase in Germany commencing May 25, 2021 Volume based pricing competitive with other COVID-19 PCR test products on the market Initial manufacturing capacity secured, additional capacity to increase based on demand XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its distribution, storage and... Read More
May 13, 2021
XPhyto Provides Update on Drug Formulation and Development Business
Rotigotine transdermal human pilot study successfully completed; program advancing to pivotal study Land purchased for construction of commercial drug manufacturing facility in Germany XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its 2021 drug formulation programs are advancing on schedule and continue to expand in scope. XPhyto is a bioscience accelerator... Read More
May 7, 2021
XPhyto Establishes Proof of Concept Station for Point-of-Care 25-minute COVID-19 PCR Test in Germany
Pilot project includes point-of-care sample collection, PCR processing and final testing of workflow logistics Project is in cooperation with a German pharmacy currently running a COVID-19 test center Rapid results with high accuracy - 20-minute PCR run plus 5-minute detection process XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) ( FSE:4XT) ("XPhyto" or the "Company") is pleased to announce it has commenced a pilot... Read More
April 28, 2021
XPhyto Pursues Market Access in Israel for its COVID-19 PCR Rapid Test
XPhyto delivered 2,000 of its 25-minute PCR tests to Israeli distributor for clinical evaluation and regulatory approval Potential customers include government institutions, private healthcare providers and neighboring countries XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that it has delivered 2,000 of its rapid 25-minute PCR tests ("Covid-ID Lab") to an... Read More
April 21, 2021
XPhyto Signs German Distribution, Storage and Logistics Agreement for 25-Minute COVID-19 PCR Test
XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that it has entered into an agreement (the "Agreement") with an established German pharmaceutical wholesaler and service provider (the "Distributor") for the distribution, storage and logistics of XPhyto's diagnostic products in Germany. The Agreement secures XPhyto a full-service distribution partner for its... Read More
April 20, 2021
XPhyto adds Top-Level Executive Talent to its Global Operations
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Mr. Wolfgang Probst as the Chief Operations Officer (COO) of XPhyto and the addition of Mr. Manfred Buchberger as the Head of Corporate Development at XP Diagnostics GmbH ("XP Diagnostics"), a wholly owned German subsidiary of the Company. With European CE-IVD approval announced March 18, 2021,... Read More
March 29, 2021
XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Recent European Approval of 25-Minute COVID-19 PCR Test
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to... Read More
March 18, 2021
XPhyto announces European Approval for 25 Minute COVID-19 PCR Test
CE Mark received for in vitro diagnostic (IVD) test for the detection of SARS-CoV-2 Rapid results with ease of use - single 20-minute PCR cycle plus 5-minute detection process High sensitivity - 104.73 c/PCR limit of detection with 95% confidence interval High specificity - zero cross-reactivity on 19x respiratory infectious disease panel High robustness - no impact on results from minor changes in process parameters 100%... Read More
March 10, 2021
XPhyto Partner Receives ISO Certification for 25-Minute COVID-19 RT-PCR Test
XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company"), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce successful EN ISO 13485 certification for the rapid point-of-care, SARS-CoV-2 RT-PCR Test System ("Covid-ID Lab"). This standardization and quality assurance certification provides authorization for distribution of Covid-ID Lab... Read More
March 4, 2021
XPhyto Completes Corporate Rebranding and Launches New Website
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company"), is pleased to announce that the Company has completed a corporate rebranding and launched a new website which can be viewed at www.xphyto.com . The rebranding decision reflects the Company's commitment to operational achievement in 2021 as a number of product development programs advance from the laboratory to the clinic. As a... Read More
February 26, 2021
XPhyto Provides Updated Comments on Promotional and Marketing Activity
XPhyto Therapeutics Corp. ( CSE :XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto" or the " Company ") at the request of IIROC and the Canadian Securities Exchange (the " CSE ") is providing additional comments to its news release and list of third-party providers dated January 22, 2021 with regards to recent promotional and investor relations activity (" Promotional Activity ") provided by said third-parties, in particular a... Read More
February 24, 2021
XPhyto Places First Order for 25-Minute Covid-19 RT-PCR Tests
XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto " or the " Company "), is pleased to announce that it has placed the first order for its rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab") from its exclusive diagnostic development partner, 3a-diagnostics GmbH ("3a"). The first order of Covid-ID Lab is for 9,600 individual tests, which are packaged in 200 kits of 48 tests... Read More
February 22, 2021
XPhyto Builds Commercial Team to Launch 25-Minute Covid-19 RT-PCR Test
XPhyto Therapeutics Corp . ( CSE:XPHY / OTCQB:XPHYF / FSE:4XT ) (" XPhyto " or the " Company "), is pleased to announce that the Company has expedited the formation of an experienced commercial team to launch its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab"). Covid-ID Lab was developed by XPhyto's exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"). XPhyto expects 3a to... Read More
February 19, 2021
XPhyto Reports Vektor Pharma GMBH Lawsuit
XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto " or the " Corporation ") is providing the following comments regarding a claim made against Vektor Pharma TF GMBH ("Vektor"), one of the Corporation's German subsidiaries. Vektor is subject to a declaratory action made by a former client and current competitor (the "Claimant") in relation to alleged breach of the terms of a development agreement... Read More
February 16, 2021
XPhyto European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test
XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto " or the " Company "), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce that all actions and procedures required for its European regulatory application for the rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR Test System ("Covid-ID Lab") have been completed. 3a expects ISO 13485 approval as... Read More
February 10, 2021
XPhyto Adds Mescaline Production to Psychedelic Medicine Programs
XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) (" XPhyto " or the " Company ") is pleased to announce that XPhyto Laboratories Inc., its wholly owned Alberta subsidiary, has added mescaline production to its psychedelic medicine programs. Further to the Company's press release dated February 3, 2021, the capacity under contract with Applied Pharmaceutical Innovation will focus on the synthesis of... Read More
February 3, 2021
XPhyto Announces Psychedelic Pharmaceutical Production Agreement
XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) (" XPhyto " or the " Company ") is pleased to announce that XPhyto Laboratories Inc. ("XPhyto Labs"), its wholly owned Alberta subsidiary, has signed an agreement (the "Agreement") with Applied Pharmaceutical Innovation ("Applied") for the synthesis of pharmaceutical grade psychedelic compounds and the parallel development of the standard operating procedures... Read More
January 28, 2021
XPhyto Announces Drug Formulation Strategy and 2021 Milestones Innovation to Impact
Construction of commercial drug manufacturing facility in Germany Four clinical studies in neurological indications in 2021 Development of oral biosensor and contract development & manufacturing Psychedelic transdermal and sublingual drug formulation development XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto " or the " Company ") is pleased to announce its drug formulation and delivery business... Read More
January 25, 2021
XPhyto Provides Comments on Promotional and Marketing Activity
XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto " or the " Corporation ") at the request of OTC Markets, is providing the following comments regarding recent promotional activity with respect to the Corporation. The Corporation has been listed on the Canadian Securities Exchange from July 2019. Since that time, the Corporation has engaged various third parties to provide media, marketing and... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS